EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells

Radu Tanasescu, Nanci Frakich, I-Jun Chou, Perla Filippini, Giulio Podda, Gao Xin, Ranjithmenon Muraleedharan, Oltita Jerca, David Onion, Cris S Constantinescu

Neurology and Therapy · 2023-12 · 12 (6) · 2041-2052

DOI: 10.1007/s40120-023-00539-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 16.09.2023. Verfasst von Radu Tanasescu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Academic Unit of Mental Health and Clinical Neuroscience, University of Nottingham, Nottingham, NG7 2UH, UK. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Natalizumab (NTZ), a monoclonal antibody against the integrin α4β1 (VLA-4) found on activated T cells and B cells, blocks the interaction of this integrin with adhesion molecules of central nervous system (CNS) endothelial cells and lymphocyte migration through the blood-brain barrier, effectively preventing new lesion formation and relapses in multiple sclerosis (MS). Whether NTZ treatment has additional effects on the peripheral immune system cells, and how its actions compare with other MS disease-modifying treatments, have not been extensively investigated. In particular, its effect on the proportions of circulating regulatory T cells (Treg) is unclear. METHODS: In this study, we investigated the effect of NTZ treatment in 12 patients with relapsing MS, at 6 and 12 months after the start of treatment. We evaluated the proportions of regulatory T cells (Treg), defined by flow cytometry as CD4+ CD25++ FoxP3+ cells and CD4+ CD25++ CD127- cells at these intervals. As an exploratory study, we also investigated the NTZ effects on the proportions of bulk T and B lymphocyte populations, and of those expressing novel the markers CD195 (CCR5), CD196 (CCR6), or CD161 (KLRB1), which are involved in MS pathogenesis but have been studied less in the context of MS treatment. The effects of NTZ were compared to those obtained with 11 patients under interferon-beta-1a (IFN-β1a) treatment, and against 9 healthy volunteers. RESULTS: We observed a transient increment in the proportion of Treg cells at 6 months, which was not sustained at 12 months. We observed a reduction in the proportion of T cells expressing CD195 (CCR5) and CD161 (KLRB1) subsets of T cells. CONCLUSION: We conclude that NTZ does not have an effect on the proportion of Treg cells over 1 year, but it may affect the expression of molecules important for some aspects MS pathogenesis, in a manner that is not shared with IFN-β1a.

Schlagwörter

Stichwörter der Autor:innen

CCR5Foxp3Multiple sclerosisNatalizumabRegulatory T cells

Autor:innen und Institutionen

  • Academic Unit of Mental Health and Clinical Neuroscience, University of Nottingham, Nottingham, NG7 2UH, UK.
  • Department of Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Nottingham Centre for MS and Neuroinflammation, Nottingham University Hospital NHS Trust, Nottingham, NG7 2UH, UK.
  • Department of Neurology, Chang Gung Memorial Hospital, Linko Branch, Taoyuan, Taiwan.
  • Wye Valley NHS Trust, Hereford, England, UK.
  • Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.

Förderung

  • Medical Research Council

Zitieren

APA

Tanasescu, R., Frakich, N., Chou, I. J., Filippini, P., Podda, G., Xin, G., Muraleedharan, R., Jerca, O., Onion, D., & Constantinescu, C. S. (2023). Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells. Neurology and Therapy, 12(6), 2041-2052. https://doi.org/10.1007/s40120-023-00539-9

Vancouver

Tanasescu R, Frakich N, Chou IJ, Filippini P, Podda G, Xin G, et al. Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells. Neurology and Therapy. 2023;12(6):2041-2052. doi:10.1007/s40120-023-00539-9

BibTeX
@article{Tanasescu2023,
  author = {Tanasescu, Radu and Frakich, Nanci and Chou, I-Jun and Filippini, Perla and Podda, Giulio and Xin, Gao and Muraleedharan, Ranjithmenon and Jerca, Oltita and Onion, David and Constantinescu, Cris S},
  title = {Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells},
  journal = {Neurology and Therapy},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {2041--2052},
  doi = {10.1007/s40120-023-00539-9}
}
Kostenlos starten →